Get started
Work

Next-Generation Molecular Imaging of Thyroid Cancer

Year: 2021
Type: article
Abstract: F]FDG has been frequently used in disease evaluation for several decades now. Recently, advances in molecular imaging have led to the development of novel tracers based on aptamer, peptide, antibody, nanobody, antibody fragment, and nanoparticle platforms. The emerging targets-including HER2, CD54, SHP2, CD33, and more-are promising targets for clinical translation soon. The significance of these tracers may be realized by outlining the way they support the management of TC. The provided examples focus on where preclinical investigations can be translated. Furthermore, advances in the molecular imaging of TC may inspire the development of novel therapeutic or theranostic tracers. In this review, we summarize TC-targeting probes which include transporter-based and immuno-based imaging moieties. We summarize the most recent evidence in this field and outline how these emerging strategies may potentially optimize clinical practice.
Source: Cancers
DOI: 10.3390/cancers13133188
Authors: Yuchen Jin, Beibei Liu, Muhsin H. Younis, Gang Huang, Jianjun Liu, Weibo Cai, Weijun Wei
Institutions: Memorial Sloan Kettering Cancer Center, Shanghai Jiao Tong University, Renji Hospital, Shanghai Sixth People's Hospital, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,376
Awards: G1201074420, G458204253, G5572808779, G8895649641, Cancer Center Support Grant, G985965059
OpenAlex ID: W3176183871
FWCI: 0.851
Cites: 191
Cited by: 14
Related to: 10